Distinctive malfunctions of calmodulin mutations associated with heart RyR2-mediated arrhythmic disease

• Published in: Biochimica et biophysica acta Vol. 1850; no. 11; pp. 2168 - 2176
• Main Authors: Vassilakopoulou, Vyronia, Calver, Brian L., Thanassoulas, Angelos, Beck, Konrad, Hu, Handan, Buntwal, Luke, Smith, Adrian, Theodoridou, Maria, Kashir, Junaid, Blayney, Lynda, Livaniou, Evangelia, Nounesis, George, Lai, F. Anthony, Nomikos, Michail
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.11.2015
• Subjects: Animals; Calcium; Calcium - metabolism; calcium channels; Calmodulin; Calmodulin - genetics; Cardiac disease; heart failure; in vitro fertilization; Long QT Syndrome - etiology; missense mutation; muscle contraction; mutants; Mutation; myocardium; patients; Polymorphic Catecholaminergic Ventricular Tachycardia; Ryanodine receptor; Ryanodine Receptor Calcium Release Channel - physiology; RyR2 calcium release channel; sarcoplasmic reticulum; Swine; tachycardia; Tachycardia, Ventricular - etiology; RyR2; CD; ECC; Calcium; Cardiac disease; LQTS; Ryanodine receptor; CaM; CPVT; Ca2; IVF; RyR2 calcium release channel; Calmodulin; SR
• ISSN: 0304-4165; 0006-3002; 1872-8006
• DOI: 10.1016/j.bbagen.2015.07.001

Calmodulin (CaM) is a cytoplasmic calcium sensor that interacts with the cardiac ryanodine receptor (RyR2), a large Ca2+ channel complex that mediates Ca2+ efflux from the sarcoplasmic reticulum (SR) to activate cardiac muscle contraction. Direct CaM association with RyR2 is an important physiological regulator of cardiac muscle excitation–contraction coupling and defective CaM–RyR2 protein interaction has been reported in cases of heart failure. Recent genetic studies have identified CaM missense mutations in patients with a history of severe cardiac arrhythmogenic disorders that present divergent clinical features, including catecholaminergic polymorphic ventricular tachycardia (CPVT), long QT syndrome (LQTS) and idiopathic ventricular fibrillation (IVF). Herein, we describe how two CPVT- (N54I & N98S) and three LQTS-associated (D96V, D130G & F142L) CaM mutations result in alteration of their biochemical and biophysical properties. Ca2+-binding studies indicate that the CPVT-associated CaM mutations, N54I & N98S, exhibit the same or a 3-fold reduced Ca2+-binding affinity, respectively, versus wild-type CaM, whereas the LQTS-associated CaM mutants, D96V, D130G & F142L, display more profoundly reduced Ca2+-binding affinity. In contrast, all five CaM mutations confer a disparate RyR2 interaction and modulation of [3H]ryanodine binding to RyR2, regardless of CPVT or LQTS association. Our findings suggest that the clinical presentation of CPVT or LQTS associated with these five CaM mutations may involve both altered intrinsic Ca2+-binding as well as defective interaction with RyR2. •Calmodulin mutations linked to cardiac pathologies CPVT and LQTS have been analysed.•The five CaM mutations studied alter the protein biochemical/biophysical properties.•Three LQTS-linked CaM mutants display profoundly reduced calcium binding affinity.•All mutants exhibit disparate ryanodine binding/interaction with RyR2 vs wild-type.•Defective calcium binding/RyR2 interaction of mutant CaM may mediate CPVT and LQTS.